Liemarto Aldrich Kurniawan, Budiono Bernadus Parish, Chionardes Melissa Angela, Oliviera Ivona, Rahmasiwi Anindita
Intensive Care Unit, Columbia Asia Hospital, Semarang, Indonesia.
Department of Internal Medicine, Columbia Asia Hospital, Semarang, Indonesia.
Ann Med Surg (Lond). 2021 Dec;72:103107. doi: 10.1016/j.amsu.2021.103107. Epub 2021 Nov 23.
Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). Recent evidences mentioned the possibility of COVID-19 as a systemic infectious and inflammatory disease. Signs and symptoms of liver and gastrointestinal system are often found in post-acute COVID-19 patients. However, there are only few data found about liver abscess and necrosis in post COVID-19 patients.
A 49-year-old man admitted to the hospital with dyspnea, nausea, loss of appetite and epigastric pain, post confirmed SARS CoV-2 severe pneumonia 1 month ago in ICU with noninvasive ventilator (NIV), enoxaparin, tocilizumab, azithromycin, levofloxacin, hydroxychloroquine, and no preexisting liver condition. Swab PCR result was negative. The result of abdominal computed tomography (CT) scan with contrast was liver abscess formation with hemorrhages measuring about 16 × 12 × 11 cm & 10 × 9x9 cm occupying most of the right lobe liver. The patient underwent exploratory laparotomy, there were multiple liver abscesses in segment 8 with parenchymal liver necrosis and abscesses in segment 7 of liver. Necrosectomy and liver abscess drainage was performed.
Pathophysiology of liver damage in post COVID-19 are direct cytotoxicity of SARS-CoV2, immune-mediated due to severe systemic inflammatory response syndrome (SIRS) in COVID-19, hypoxemia, vascular changes due to coagulopathy, endothelitis or congestion from right heart failure, and drug-induced liver injury (DILI).
The possible pathophysiology of liver abscess and necrosis in post COVID-19 should be considered in monitoring and management for both COVID-19 patients and post COVID-19 patients.
2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV2)引起的急性呼吸道感染。最近的证据表明,COVID-19有可能是一种全身性感染和炎症性疾病。在急性COVID-19康复患者中,常发现肝脏和胃肠道系统的体征和症状。然而,关于COVID-19康复患者出现肝脓肿和肝坏死的数据却很少。
一名49岁男性因呼吸困难、恶心、食欲不振和上腹部疼痛入院。1个月前,他在重症监护病房(ICU)确诊为SARS-CoV2重症肺炎,当时使用了无创呼吸机(NIV)、依诺肝素、托珠单抗、阿奇霉素、左氧氟沙星、羟氯喹,且既往无肝脏疾病史。咽拭子PCR检测结果为阴性。腹部增强CT扫描结果显示肝脓肿形成,伴有出血,大小约为16×12×11厘米和10×9×9厘米,占据了右肝叶的大部分区域。患者接受了剖腹探查术,发现肝8段有多个肝脓肿,肝实质坏死,肝7段也有脓肿。进行了坏死组织切除术和肝脓肿引流术。
COVID-19康复后肝损伤的病理生理机制包括SARS-CoV2的直接细胞毒性、COVID-19严重全身炎症反应综合征(SIRS)介导的免疫反应、低氧血症、凝血病导致的血管变化、内皮炎症或右心衰竭引起的充血以及药物性肝损伤(DILI)。
在对COVID-19患者及其康复后的患者进行监测和管理时,应考虑COVID-19康复后出现肝脓肿和肝坏死的可能病理生理机制。